The EMA’s Committee for Medicinal Products for Human Use (CHMP) determined that expected clinical benefits of seladelpar include delayed development of liver fibrosis and cirrhosis, potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback